Meeting
2020 Genitourinary Cancers Symposium
Association of body composition with survival and efficacy of first-line treatment in patients with castration-resistant prostate cancer.
Authors
Jae Young Joung
Center for Prostate Cancer, National Cancer Center, Goyang, South Korea
Jae Young Joung , Sahyun Pak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 115)
Abstract #
115
Poster Bd #
E17
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
First Author: Naoki Terada
Poster
2014 Genitourinary Cancers Symposium
Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients.
First Author: Ernest N. Lo
Poster
2011 ASCO Annual Meeting
Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels.
First Author: C. W. Reuter
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.
First Author: Yushi Naito